Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
September 11, 2023
-
BUSINESS After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
September 8, 2023
-
BUSINESS Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
-
ORGANIZATION Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
-
REGULATORY Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
-
BUSINESS Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
-
BUSINESS Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
-
REGULATORY Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
-
REGULATORY MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
-
REGULATORY Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
-
BUSINESS Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
-
REGULATORY MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
-
REGULATORY Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
-
BUSINESS First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
-
ORGANIZATION JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
-
REGULATORY Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
-
REGULATORY Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
August 28, 2023
-
REGULATORY MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
August 25, 2023
-
ACADEMIA Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
-
REGULATORY Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
August 24, 2023
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…